Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Galliford, Mattioli Woods and Telecom Plus chairs

Tue, 15th Mar 2022 15:31

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and Tuesday and not separately reported by Alliance News:

----------

Galliford Try Holdings PLC - Uxbridge, England-based construction company - Hires Alison Wood to be next non-executive chair, replacing Peter Ventress, who will step down from the board on September 15 after serving as a director for seven years. Wood will join the board on April 1 and take over as chair upon Ventress's departure. Wood was director of strategy & corporate development at National Grid PLC and strategy director at BAE Systems PLC. Currently, she is senior independent director of Oxford Instruments PLC and a non-executive director of TT Electronics and Capricorn Energy PLC, formerly Cairn Energy.

----------

Mattioli Woods PLC - Leicester, England-based asset manager - David Kiddie is confirmed as non-executive chair, following regulatory approval. Kiddie's appointment was first announced back in October. He replaces Joanne Lake, who steps down from the board immediately.

----------

Telecom Plus PLC - London-based provider of energy, communications and insurance for residences and businesses - Charles Wigoder moves from executive chair to non-executive chair, while non-executive directors Melvin Lawson and Julian Schild retire from the board, effective from annual general meeting in July. Telecom Plus is looking to recruit an additional independent non-executive director. It says the changes are to increase the number of independent non-executive directors on the board, following the appointment back in November of Stuart Burnett as co-chief executive officer alongside Andrew Lindsay.

----------

Gattaca PLC - Hampshire, England-based engineering and technology recruitment firm - Chief Executive Officer Kevin Freeguard and Chief Financial Officer Salar Farzad both will leave Gattaca at the end of April. Freeguard has been with Gattaca since 2018 and Farzad since 2017. Gattaca says it was Freeguard's "original intention to leave at the end of this year but he felt, and the board agreed, that given the scale of further improvement required in the business, an earlier change of leadership was in the group's interest." Meanwhile, Farzad believes "the business will be best served by a CFO who can partner with the new CEO for the long term." Chief Customer Officer Matt Wragg is promoted to CEO, starting April 1, having been with Gattaca for 20 years. Oliver Whittaker will succeed Farzad. Whittaker joined Gattaca in 2017 as director of financial planning, having been UK finance director for Fitness First.

----------

Microsaic Systems PLC - Surrey-based mass spectrometry equipment - CEO Glenn Tracey will leave Microsaic on March 31, rather than at the AGM in June, as previously planned. From April 1 until a successor as CEO is found, Chair Gerry Brandon will act as executive chair.

----------

GlaxoSmithKline PLC - Brentford, England-based pharmaceutical firm - Names more directors for the board of Haleon, the new company to be formed from the demerger of the GSK Consumer Healthcare business in July. Dave Lewis, the former CEO of grocer Tesco PLC, previously had been named as chair. Vindi Banga, the current senior independent non-executive director of GSK, will be senior independent non-executive director of Haleon. Vivienne Cox, another non-executive director of GSK, also will be a non-executive director of Haleon. Meanwhile, John Young has been appointed as a non-executive director by Pfizer Inc, which holds a third of the current GSK Consumer Healthcare. Young currently is a director of the GSK-Pfizer joint-venture that will become Haleon. Two other non-executive directors of Haleon will be Tracy Clarke and Deirdre Mahlan. Clarke currently is a non-executive director of TP ICAP PLC. Mahlan is a director of Experian PLC and of Kimberly-Clark Corp. Two executive directors will be Haleon CEO Designate Brian McNamara and CFO Designate Tobias Hestler.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.